A state-of-the-art, multipod facility for studies of tuberculosis, influenza and human immunodeficiency virus (HIV)

The Containment Level 3 (CL3) Platform has three independent pods that meet the highest safety standards defined by Canadian Biosafety Standards and Guidelines (PHAC and CFIA).

The facility is available to RI-MUHC researchers, affiliated collaborators and external researchers whose work requires a facility where properly trained users can manipulate various pathogenic organisms.

Users of the CL3 Platform must follow the established Standard Operating Procedures (SOPs), as defined in the platform’s SOP manual.

Director: Marcel Behr, MD, M.Sc.
Platform Manager: Fiona McIntosh, B.Sc.
Click here to contact us

 

News and Events